Moreover, tau phosphorylation at specific sites such as Ser202, Thr205, Thr231, Thr217, and Thr181 may serve as cerebrospinal fluid (CSF) biomarkers for the preclinical stage of AD [25,26]. This evidence concerns the gene MAPT and Alzheimer disease.